Follicular Lymphoma News and Research

Latest Follicular Lymphoma News and Research

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines -produced from healthy and tumour cells from the patient him or herself- and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

1 Dec 2009

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

30 Nov 2009

Professor Suzanne Cory receives award for her work in cancer and immunogenetics

Professor Suzanne Cory, the former director of the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, has been named the recipient of the 2009 Pearl Meister Greengard Prize.

24 Oct 2009

Biogen Idec announces total revenues of $1.12 billion for third quarter 2009

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today reported its third quarter 2009 results.

20 Oct 2009

Manchester scientists test radioimmunotherapy in early phase clinical trials

MANCHESTER SCIENTISTS are testing an emerging therapy called radioimmunotherapy (RIT) in early phase clinical trials, according to a presentation at the NCRI Cancer Conference in Birmingham today (Wednesday).

9 Oct 2009

ESMO recognises outstanding achievements of leading cancer specialists

The European Society for Medical Oncology (ESMO) has recognized the outstanding achievements of three leading cancer specialists with its three prestigious annual awards: the 2009 ESMO Award, Hamilton Fairley Award and ESMO Lifetime Achievement Award.

23 Sep 2009

Leading oncology experts to discuss management of hematological malignancies

Oncology experts from leading cancer organizations from around the country, including the John Theurer Cancer Center, MD Anderson Cancer Center, the Mayo Clinic, Dana Farber Cancer Institute and the National Cancer Institute, will discuss trends in patient care, novel therapies through clinical trials and emerging concepts in the management of hematological malignancies.

23 Sep 2009

Genentech releases Phase III PRIMA study findings

Genentech, Inc., a wholly-owned member of the Roche Group and Biogen Idec, today announced that a Phase III study (PRIMA) showed that patients with follicular lymphoma who continued receiving Rituxan (rituximab) alone after responding to Rituxan and chemotherapy lived longer without their disease worsening (progression-free survival or PFS) than those who did not continue to receive Rituxan.

17 Sep 2009

Discovery of gene linked to follicular lymphoma

California and Arizona researchers have identified a gene variant that carries nearly twice the risk of developing an increasingly common type of blood cancer, according to a study published online today by the science journal Nature Genetics.

20 Jul 2009

Monoclonal antibody cancer therapy

The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with the promise that they could be developed into therapies that were highly specific to cancer cells, killing them with few or no side effects.

6 Apr 2009

Rituximab useful for advanced indolent lymphoma

A new study has found for the first time that maintenance therapy with the novel antibody, rituximab (MR) following cyclophosphamide, vincristine and prednisone (CVP) therapy improves progression-free survival in patients with stage III-IV indolent lymphoma, according to Howard S. Hochster, M.D. of NYU Langone Medical Center, lead author of a recent study published online ahead of print in the Journal of Clinical Oncology.

11 Mar 2009

Rituximab maintenance therapy improves survival in patients with relapsed follicular lymphoma

atients with relapsed or refractory follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than patients who do not receive this treatment, according to a meta-analysis of randomized trials in the February 10 online issue of the Journal of the National Cancer Institute.

10 Feb 2009

Statins do not interfere with Rituximab treatment for lymphomas

Statins, drugs widely prescribed to lower cholesterol, do not interfere with a commonly used medication to treat lymphomas, according to a Mayo Clinic study presented at the 50th Annual Meeting of the American Society of Hematology in San Francisco.

8 Dec 2008

Kiadis Pharma receives two orphan drug designations for Reviroc

Kiadis Pharma has announced that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL).

8 Dec 2008

NCI awards Wilmot scientists $1.6 million to study lymphoma treatments

The National Cancer Institute has tapped a team of scientists at the James P. Wilmot Cancer Center to lead a $1.6 million in research program to improve lymphoma treatment, an area of excellence in research and care for the University of Rochester Medical Center.

12 Aug 2008

Individualized therapies for non-Hodgkin's lymphoma identified with PET

Positron emission tomography (PET) could be an important tool for identifying non-Hodgkin's lymphoma patients who are likely to respond well to treatment with 90 ibritumomab tiuxetan (IT)-the first radioimmunotherapy treatment approved for use by the U.S. Food and Drug Administration, said researchers at the Society of Nuclear Medicine's 55th Annual Meeting.

16 Jun 2008

Drugs in the pipeline: new therapies that could change treatment strategies

The investigational drug AZD2171 (cediranib) may help shrink tumors and prolong survival of patients with a relatively common, aggressive type of brain cancer, according to results from a clinical trial conducted by Boston researchers.

16 Apr 2008

Genmab announces HuMax-CD32b pre-clinical program

Genmab A/S has announced a new pre-clinical antibody program called HuMax-CD32b. This fully human IgG1,k antibody targets the CD32b receptor found on immune cells and hematological tumors.

7 Jan 2008

Mild chemo before stem cell transplant causes long-term remission of follicular lymphoma

Treating relapsed follicular lymphoma patients with a milder chemotherapy regimen before they receive a blood stem cell transplant from a donor resulted in long-term complete remission for 45 of 47 patients in a clinical trial, researchers at The University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.

10 Dec 2007

Study finds lymphoma drug effective over long term

Eight years after being treated with a new drug for non-Hodgkin's lymphoma, 86 percent of patients were still alive and half had not had a relapse of their disease, according to researchers from the University of Michigan Comprehensive Cancer Center.

5 Jun 2007